Clinical Trial Update: An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy [Phase 2, Phase 3]

View source ↗

Summary

An extension study (Fx-005) of Fx-1006A in transthyretin-related hereditary amyloidosis with polyneuropathy has completed, providing long-term safety and clinic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-related Hereditary Amyloidosis with Polyneuropathy

Drugs mentioned

• Fx-1006A

Snippet

Sponsor: Pfizer | Conditions: Familial Amyloid Polyneuropathy, ATTR-PN | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-12-17